predicted
include, without limitation, commercial and governmental reimbursement
decisions, compliance and regulatory risks, the Company's ability to hire
personnel and manage its growth and the competitive landscape within our
industry. These and other risks and uncertainties are detailed in the
Company's Annual Report on Form 10-K for the full-year period ended
December 31, 2007, most recent Quarterly Report on Form 10-Q and subsequent
filings with the United States Securities and Exchange Commission. Undue
reliance should not be placed on forward-looking statements, which speak
only as of the date they are made. The Company undertakes no obligation to
update any forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the occurrence
of unanticipated events.
[Financial tables follow]
GENOPTIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenues $27,825 $13,948 $50,123 $24,599
Cost of revenues 11,206 5,393 20,381 10,030
Gross profit 16,619 8,555 29,742 14,569
Operating expenses:
Sales and marketing 5,170 2,421 9,431 4,742
General and administrative 5,918 2,131 10,306 4,265
Research and development 354 142 671 320
Total operating expenses 11,442 4,694 20,408 9,327
Income from operations 5,177
'/>"/>
SOURCE Genoptix, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
Genoptix Reports Strong Financial Results for First Quarter 20082.
Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference3.
Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record4.
Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference5.
Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference6.
Genoptix Announces Pricing of Secondary Public Offering7.
Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock8.
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 20079.
Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 200810.
Genoptix, Inc. Announces Pricing for Initial Public Offering11.
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update